Skip to main content

Table 1 Main baseline characteristics of 86 HIV/AgHBs co-infected patients

From: Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil

Variables

n

Male gender (%)

83 (96. 5%)

Mean age (years)

42 (± 7. 2)

Mode of HIV transmission

 

-Men who have unprotected sex with men (%)

64 (74. 4%)

- Exchange of needles among intravenous drug users (%)

16 (18. 6%)

Clinical Variables

 

- Advanced hepatic disease

17 (19. 7%)

-Non adherence to treatment

09 (10. 4%)

Treatment Given-HAART

 

-Previous use of antiretroviral therapy

81 (94. 1%)

-Patients under LAM + TDF combination therapy

48 (56. 0%)

-Patients under LAM monotherapy

31 (36. 0%)

-Previous use of either LAM or TDF

81 (94. 1%)

- Previous use of LAM

79 (91. 8%)

- Previous use of TDF

48 (55. 8%)

-Time of use of TDF (months)

4-21

-Time of use of LAM (months)

7-144

-Laboratory Variables

 

HBeAg positive

42 (48. 9%)

HBV-DNA < 60 UI/mL

50 (58. 1%)

HBV-DNA > 60 UI/mL

34 (39. 5%)

HBV-DNA unknown

02 (2. 32%)

HBV Genotype

 

-genotype A

21

-genotype D

05

-genotype G

05

-genotype F

03

-CD4 cell count, median cells/μ1

545 (± 250)

-Baseline HIV RNA < 400 copies/mL

73 (85%)

ALT level, normal

54 (62. 7%)

- ALT level > 1. 5 × ULN†

32 (37. 2%)

-Anti-HCV positive

20 (23. 2%)

-Anti-HDV positive

01 (1. 1%)

  1. ULN†-Upper Limit of Normality; LAM = lamivudine; TDF = tenofovir